KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to -$99.6 million.

  • Pacira BioSciences' Net Income towards Common Stockholders rose 103.79% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 123.63%. This contributed to the annual value of -$99.6 million for FY2024, which is 337.30% down from last year.
  • Per Pacira BioSciences' latest filing, its Net Income towards Common Stockholders stood at -$99.6 million for FY2024, which was down 337.30% from $42.0 million recorded in FY2023.
  • Pacira BioSciences' Net Income towards Common Stockholders' 5-year high stood at $145.5 million during FY2020, with a 5-year trough of -$99.6 million in FY2024.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was $15.9 million (2022), whereas its average is -$13.9 million.
  • Per our database at Business Quant, Pacira BioSciences' Net Income towards Common Stockholders surged by 1,421.01% in 2020 and then plummeted by 337.30% in 2024.
  • Pacira BioSciences' Net Income towards Common Stockholders (MRY) stood at $145.5 million in 2020, then crashed by 71.15% to $42.0 million in 2021, then plummeted by 62.10% to $15.9 million in 2022, then surged by 163.72% to $42.0 million in 2023, then tumbled by 337.30% to -$99.6 million in 2024.
  • Its Net Income towards Common Stockholders stands at -$99.6 million for FY2024, versus $42.0 million for FY2023 and $15.9 million for FY2022.